Drug Discovery Nexus East Coast 2020

Drug Discovery Nexus East Coast is organized by Procurement Direct Ltd and will be held from Apr 23 - 24, 3030 at King Of Prussia, Pennsylvania, United States of America.

Description:
This distinctive program is designed in such a way that one day is purely focused on early drug discovery including modern medicinal chemistry strategies, new therapeutic strategies beyond conventional biologics & Drug Design and day two is dedicated to novel approaches in drug discovery including the new era of artificial intelligence and machine learning with regards to drug discovery.

Benifits of Attending:
• Enrich topics
• Meet experts & influencers face to face
• Focused Networking
• Information about the valuable insights of industry
• Virtual synchronization
• Pronouncement Authority
• Distinct Contrast
• Position yourself as an expert
• Direct contact with potential clients and costumers
• Get fresh ideas and solutions for your business
• Stay current with trends by learning from powerful speakers
• Observe visual cues from presenters & other attendees
• Gain insight into how new techniques are being utilized for Drug Discovery

Job Functions:
• CSO
• Head, Biology & Translational Pharmacology
• Head, Oncology Chemistry
• Dir Discovery Chemistry & Technology
• Head of Molecular & Computational Toxicology
• VP, R&D
• Director DMPK
• CEO
• Head, Cancer Biology & Pharmacology
• Dir CAR Program, Research & Discovery
• Chief Scientist, R&D
• Director R&D Management
• Director Biomarker Discovery
• Senior Director Preclinical
• Director Pharmacology
• Senior Group Leader Medicinal Chemistry
• VP Preclinical R&D
• VP Chemistry
• Director Preclinical Research
• Director Preclinical Drug Safety
• Head, PTS Discovery Genome Editing

Tracks & Sessions:
• Target identification and Validation.
• Confrontations in cell based phenotypic drug discovery: What aspects of phenotypic drug discovery are most advantages in drug discovery.
• Recombinant DNA technology.
• Integrated fragment based lead discovery.
• CRISPR Screening for target and off target identification: Challenges within shadow of CRISPR.
• Exploring PPIs and Nucleic Acid complexes for therapeutics interventions.